Phase 2 Endometrial Cancer Trial, Recruiting NCT07424664 Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT07424664
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You fully understand the study, agree to take part voluntarily, and are willing to sign a consent form.
  • You are a woman between 18 and 75 years old (inclusive).
  • Your doctor estimates you are expected to live for at least 3 months or more.
  • Your cancer has been confirmed by a tissue sample (biopsy) to be squamous cell carcinoma of the cervix, vagina, or vulva.
  • You have already received at least one standard treatment that included both a platinum-based chemotherapy and an immunotherapy drug, and you have had no more than 4 previous lines of treatment in total.
  • You are generally well enough to carry out light daily activities, with little or no limitation (this is measured on a standard scale called ECOG — confirm with trial site if unsure of your score).
  • You have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines.
  • Your blood counts are within acceptable ranges, meaning your bone marrow is producing enough blood cells (confirm specific values with trial site).
  • Your liver and kidney function blood test results are within acceptable ranges (confirm specific values with trial site).
  • You are not pregnant or breastfeeding, and if you could become pregnant, you have had a negative pregnancy blood test within 28 days before joining and agree to use effective contraception from signing the consent form until 6 months after your last dose of the study drug.
  • You agree to provide blood and tissue samples for the study.

Who may not be able to join:

  • You have a known allergy or serious reaction to any of the study drugs or their ingredients.
  • You have taken certain medications that strongly interact with the study drug — including some epilepsy medicines (such as phenytoin, phenobarbital, or carbamazepine), rifampicin, rifabutin, or St. John's Wort in the past 2 weeks; or certain antibiotics, antifungals, or HIV medicines, or consumed grapefruit juice in the past week (confirm full list with trial site).
  • Your cancer has spread to the brain, spinal cord, or the lining around the brain or spinal cord.
  • You have an uncontrolled ongoing illness (such as a serious infection, uncontrolled high blood pressure, or uncontrolled diabetes), or a mental health or personal situation that would make it difficult to follow the study requirements.
  • You have a confirmed bowel blockage on a scan, or a history of inflammatory bowel disease, Crohn's disease, ulcerative colitis, or major bowel surgery that caused long-term diarrhoea.
  • You have an active hepatitis B or hepatitis C infection with detectable virus levels in your blood (confirm specific levels with trial site).
  • You have HIV infection (confirmed by a positive HIV antibody test).
  • You have had major surgery or a serious injury within the 30 days before starting the study, or have major surgery planned within 30 days after starting.
  • You are pregnant, breastfeeding, or could become pregnant and are unwilling to use effective contraception.
  • Your doctor considers there to be any other reason you would not be suitable for this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Guiling Li, Doctor, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China

Phone: 027-83262598

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry
ClinicalTrials.gov
Start date
11 June 2026
Est. completion
15 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The objective response rate of the treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov